Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:13:26 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Mendus Q2 2023 - Funding secured for coming phase II trials

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Mendus Q2 2023 - Funding secured for coming phase II trials

2023-08-29 11:11:00

Redeye provides its comment on Mendus’ Q2 2023 report. We positively view the company's recent capital raise for continued clinical phase II development of vididencel and ilixadencel. However, it was highly dilutive for shareholders who did not subscribe to their pro-rata share. We finetune estimated clinical timelines for Mendus’ drug candidates in our model and thus adjust our estimates and valuation accordingly.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/